Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tetanus Vaccine Response Post-ASCT in Multiple Myeloma
NCT02700841Phase 2Terminated
- Sponsor
- University of Nebraska
- Start
- Jan 2020
- Primary completion
- Dec 2022
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of autologous lymphocyte infusion in multiple myeloma (MM), sponsored by University of Nebraska. Started Jan 2020; status: terminated.
02
Drugs
autologous lymphocyte infusion
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02700841.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02700841.